$ARTH
Arch Therapeutics, Inc.

2016 Q1 Form 10-Q Financial Statement

#000114420416096898 Filed on April 28, 2016

View on sec.gov

Income Statement

Concept 2016 Q1 2015 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $870.0K $850.0K
YoY Change 2.35% 4.94%
% of Gross Profit
Research & Development $386.3K $402.5K
YoY Change -4.03% -17.37%
% of Gross Profit
Depreciation & Amortization $0.00
YoY Change
% of Gross Profit
Operating Expenses $1.255M $1.256M
YoY Change -0.08% -3.08%
Operating Profit -$1.255M -$1.256M
YoY Change -0.08% -3.08%
Interest Expense $66.82K $50.56K
YoY Change 32.18% 82.09%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$1.250M -$830.0K
YoY Change 50.6% -90.1%
Income Tax
% Of Pretax Income
Net Earnings -$1.253M -$834.0K
YoY Change 50.25% -90.05%
Net Earnings / Revenue
Basic Earnings Per Share -$0.01
Diluted Earnings Per Share -$11.41K -$10.91K
COMMON SHARES
Basic Shares Outstanding 109.6M shares 76.08M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2016 Q1 2015 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.670M $570.0K
YoY Change 192.98% -78.33%
Cash & Equivalents $1.669M $573.6K
Short-Term Investments
Other Short-Term Assets $90.00K $30.00K
YoY Change 200.0% 0.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $1.759M $606.0K
YoY Change 190.31% -77.22%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $632.00 $0.00
YoY Change -100.0%
TOTAL ASSETS
Total Short-Term Assets $1.759M $606.0K
Total Long-Term Assets $632.00 $0.00
Total Assets $1.760M $606.0K
YoY Change 190.41% -77.3%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $140.0K $204.1K
YoY Change -31.41% 104.1%
Accrued Expenses $160.0K $330.0K
YoY Change -51.52% 120.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $100.0K $410.0K
YoY Change -75.61%
Total Short-Term Liabilities $400.0K $1.392M
YoY Change -71.27% -68.14%
LONG-TERM LIABILITIES
Long-Term Debt $970.0K $960.0K
YoY Change 1.04% 1.05%
Other Long-Term Liabilities $270.0K $4.180M
YoY Change -93.54% -28.42%
Total Long-Term Liabilities $1.243M $5.143M
YoY Change -75.84% -24.25%
TOTAL LIABILITIES
Total Short-Term Liabilities $400.0K $1.392M
Total Long-Term Liabilities $1.243M $5.143M
Total Liabilities $1.642M $6.535M
YoY Change -74.88% -41.44%
SHAREHOLDERS EQUITY
Retained Earnings -$18.13M -$13.23M
YoY Change 37.06%
Common Stock $18.14M $7.300M
YoY Change 148.47%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $120.0K -$5.929M
YoY Change
Total Liabilities & Shareholders Equity $1.760M $606.0K
YoY Change 190.41% -77.3%

Cashflow Statement

Concept 2016 Q1 2015 Q1
OPERATING ACTIVITIES
Net Income -$1.253M -$834.0K
YoY Change 50.25% -90.05%
Depreciation, Depletion And Amortization $0.00
YoY Change
Cash From Operating Activities -$1.190M -$960.0K
YoY Change 23.96% -6.8%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 40.00K 750.0K
YoY Change -94.67% -72.43%
NET CHANGE
Cash From Operating Activities -1.190M -960.0K
Cash From Investing Activities
Cash From Financing Activities 40.00K 750.0K
Net Change In Cash -1.150M -210.0K
YoY Change 447.62% -112.43%
FREE CASH FLOW
Cash From Operating Activities -$1.190M -$960.0K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016Q1 us-gaap Cash
Cash
1669249 USD
CY2015Q3 us-gaap Cash
Cash
3960100 USD
CY2016Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
90119 USD
CY2015Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
42919 USD
CY2016Q1 us-gaap Assets Current
AssetsCurrent
1759368 USD
CY2015Q3 us-gaap Assets Current
AssetsCurrent
4003019 USD
CY2016Q1 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
163386 USD
CY2015Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
421706 USD
CY2016Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
1662 USD
arth Noncash Interest Expense On Notes Payable
NoncashInterestExpenseOnNotesPayable
78320 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-11029 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
47200 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
28267 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-96146 USD
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
58650 USD
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-64101 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-1809920 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-2330851 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
1550000 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
40000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-259920 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-2290851 USD
CY2015Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3960100 USD
CY2015Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
573600 USD
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
800000 USD
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
40000 USD
us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
-3849448 USD
us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
-192128 USD
CY2016Q1 us-gaap Derivative Loss On Derivative
DerivativeLossOnDerivative
0 USD
CY2015Q3 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
245478 USD
CY2016Q1 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
0 USD
CY2015Q3 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
335092 USD
CY2016Q1 us-gaap Long Term Notes Payable
LongTermNotesPayable
972353 USD
CY2015Q3 us-gaap Long Term Notes Payable
LongTermNotesPayable
966824 USD
CY2016Q1 us-gaap Accounts Payable And Accrued Liabilities Noncurrent
AccountsPayableAndAccruedLiabilitiesNoncurrent
270500 USD
CY2015Q3 us-gaap Accounts Payable And Accrued Liabilities Noncurrent
AccountsPayableAndAccruedLiabilitiesNoncurrent
210000 USD
CY2016Q1 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
1242853 USD
CY2015Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
1176824 USD
CY2016Q1 us-gaap Liabilities
Liabilities
1641854 USD
CY2015Q3 us-gaap Liabilities
Liabilities
2462902 USD
CY2016Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
18139021 USD
CY2015Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
17154945 USD
CY2016Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-18131931 USD
CY2015Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-15722220 USD
CY2016Q1 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
100000 USD
CY2015Q3 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
473747 USD
us-gaap Derivative Loss On Derivative
DerivativeLossOnDerivative
1924186 USD
us-gaap Derivative Loss On Derivative
DerivativeLossOnDerivative
0 USD
CY2015Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
853177 USD
CY2015Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
402495 USD
CY2016Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
386285 USD
CY2015Q1 us-gaap Operating Expenses
OperatingExpenses
1255672 USD
CY2016Q1 us-gaap Operating Expenses
OperatingExpenses
1254718 USD
CY2015Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1255672 USD
CY2016Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1254718 USD
CY2015Q1 us-gaap Interest Expense
InterestExpense
50556 USD
CY2016Q1 us-gaap Interest Expense
InterestExpense
66823 USD
CY2015Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
1096278 USD
CY2016Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
54982 USD
CY2015Q1 arth Gain On Exercise Of Warrants
GainOnExerciseOfWarrants
0 USD
CY2016Q1 arth Gain On Exercise Of Warrants
GainOnExerciseOfWarrants
13503 USD
CY2015Q1 us-gaap Derivative Loss On Derivative
DerivativeLossOnDerivative
624016 USD
CY2015Q1 us-gaap Net Income Loss
NetIncomeLoss
-833966 USD
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-1253056 USD
us-gaap Net Income Loss
NetIncomeLoss
-454821 USD
us-gaap Net Income Loss
NetIncomeLoss
-2409711 USD
us-gaap Share Based Compensation
ShareBasedCompensation
609272 USD
us-gaap Share Based Compensation
ShareBasedCompensation
358330 USD
arth Noncash Interest Expense On Notes Payable
NoncashInterestExpenseOnNotesPayable
210569 USD
CY2016Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1669249 USD
arth Change To Gain Or Loss On Warrant Modification
ChangeToGainOrLossOnWarrantModification
-1924186 USD
arth Change To Gain Or Loss On Warrant Modification
ChangeToGainOrLossOnWarrantModification
0 USD
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
536278 USD
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
0 USD
us-gaap Increase Decrease In Restricted Cash For Operating Activities
IncreaseDecreaseInRestrictedCashForOperatingActivities
-52500 USD
us-gaap Increase Decrease In Restricted Cash For Operating Activities
IncreaseDecreaseInRestrictedCashForOperatingActivities
-8625 USD
CY2013Q2 arth Increase In Aggregate Number Of Shares
IncreaseInAggregateNumberOfShares
3000000 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.7657 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.1944 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0058 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0240 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
10776500 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
37500 shares
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
10739000 shares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
9816751 shares
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
10739000 shares
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.30
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
arth Share Based Compensation Arrangement By Share Based Payment Award Options Awarded Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAwardedWeightedAverageRemainingContractualTerm
P0Y
arth Share Based Compensation Arrangement By Share Based Payment Award Options Exercised Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm
P0Y
arth Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm
P0Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y8M1D
arth Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm
P4Y10M13D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P5Y8M1D
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 USD
arth Share Based Compensation Arrangement By Share Based Payment Award Options Awarded Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAwardedAggregateIntrinsicValue
0 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0 USD
arth Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited In Period Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodAggregateIntrinsicValue
0 USD
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
593828 USD
arth Share Based Compensation Arrangement By Share Based Payment Award Options Vested In Period Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodAggregateIntrinsicValue
434330 USD
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
593828 USD
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0.22
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.31
arth Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice
0.31
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
0.31
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
4381704 shares
CY2016Q1 us-gaap Derivative Fair Value Of Derivative Liability Amount Not Offset Against Collateral
DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral
354988 USD
us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
395012 USD
CY2016Q1 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
972353 USD
CY2015Q3 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
966824 USD
CY2016Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
2764 USD
CY2014Q4 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
224000 USD
CY2015Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2016Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2016Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2015Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2015Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
107592205 shares
CY2016Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
110423588 shares
CY2016Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
110423588 shares
CY2015Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
107592205 shares
CY2016Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.01
CY2015Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.01
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.02
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.01
CY2016Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
109524010 shares
CY2015Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
76076487 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
109069824 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
74716734 shares
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0 USD
us-gaap Interest Expense Debt
InterestExpenseDebt
5529 USD
CY2015Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
2764 USD
us-gaap Interest Expense Debt
InterestExpenseDebt
5529 USD
us-gaap Use Of Estimates
UseOfEstimates
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <u><font style="FONT-SIZE: 10pt">Use of Estimates</font></u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <u><font style="FONT-SIZE: 10pt">Concentration of Credit Risk</font></u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash. The Company maintains its cash in bank deposit accounts, which, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts. The Company believes it is not exposed to any significant credit risk on cash.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2015Q1 arth Gain Loss On Warrant Derivative Modification
GainLossOnWarrantDerivativeModification
624016 USD
CY2016Q1 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
100000 USD
CY2015Q3 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
605000 USD

Files In Submission

Name View Source Status
0001144204-16-096898-index-headers.html Edgar Link pending
0001144204-16-096898-index.html Edgar Link pending
0001144204-16-096898.txt Edgar Link pending
0001144204-16-096898-xbrl.zip Edgar Link pending
arth-20160331.xml Edgar Link completed
arth-20160331.xsd Edgar Link pending
arth-20160331_cal.xml Edgar Link unprocessable
arth-20160331_def.xml Edgar Link unprocessable
arth-20160331_lab.xml Edgar Link unprocessable
arth-20160331_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
v437517_10q.htm Edgar Link pending
v437517_ex31-1.htm Edgar Link pending
v437517_ex31-2.htm Edgar Link pending
v437517_ex32-1.htm Edgar Link pending